Naar homepage     
Chronische Cerebro-Spinale Veneuze Insufficiëntie
Aanmelden op het CCSVI.nl forum
Lees Voor (ReadSpeaker)    A-   A+
Over CCSVI.nl | Zoeken | Contact | Forum
PayPal, de veilige en complete manier van online betalen.

iDeal
CCSVI.nl is onderdeel van de
Franz Schelling Stichting
meer informatie
  
Thursday, May 24, 2012 3:24 AM | Venöse Multiple Sklerose, CVI & SVI, CCSVI Volg link
Adverse events kidney transplant Fingolimod/GYLENYA, NOVARTIS & other crimes

Alison Fisher is reporting: Marketing meeting at Novartis probably went like this ".....so no good for kidney patients... lets rework the stats, rebrand it as Gilenya and give it to that favoured dumping ground for recycled drugs.... MS patients... we can get away with giving them anything whether it stops their hearts, gives them cancer, macular edema....."

The European Medicines Agency says it should not be prescribed to patients with CEREBROVASCULAR PROBLEMS... ie problems with blood flow to the head.. oops..

Alison Fisher: https://docs.google.com/viewer?a=v&q=cache%3A19VetX9bo-MJ%3Awww.novartisclinicaltrials.com%2Fwebapp%2Fclinicaltrialrepository%2FdisplayFile.do%3FtrialResult%3D2372+adverse+events+kidney+transplant+fingolimod&hl=en&gl=uk&pid=bl&srcid=ADGEESgf2F4F_G2OaPiVBm1kPaaGyRynuwHQ98c9nyAUMPllACHbKzg4sylvyDJlRIdd-v-I2MKYt0v_OGm6W2wkGsl-fE1zVGfDJ1wTHMjfYSu_lzuic8fGO8yRgPBcVhbKzDqzH8tF&sig=AHIEtbReVskIsJK0f6ioXGpPjtrLTcUEyQ

Adverse events page 87 onwards for pwMS
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf

The EMA says it should not be prescribed to people with cerebrovascular disease... uh oh - isn't that nearly all of us then..
http://www.reuters.com/article/2012/04/20/us-novartis-gilenya-idUSBRE83J0EG20120420

The EMA concludes on page 2 of this report:
"However, considering that certain patients have an increased risk of cardiovascular problems, particularly those with a history of cardiovascular or CEREBROVASCULAR PROBLEMS (problems with the blood supply to the brain), and those who are taking other medicines that lower the heart rate, the Committee concluded that Gilenya is not recommended in these patients"
http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848107/

FTY720 (fingolimod) increases vascular tone a... [Br J Pharmacol. 2012] - PubMed - NCBI http://www.ncbi.nlm.nih.gov/pubmed/22251137

Source: http://www.facebook.com/photo.php?fbid=3897657798332&set=a.3475436083053.2160140.1185729368&type=1&theater